Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ViaCyte, Inc.
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
Cordis plans to acquire MedAlliance, the developer of the Selution SLR drug-eluting vascular balloon, for up to $1.135bn. As part of the deal, Cordis will immediately begin to co-promote Selution SLR in every market where it is available.
Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.
- Drug Delivery
- Implantable Devices
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- BetaLogics Internal Venture